UPLC-QE-MS combined network pharmacological analysis of the mechanism of ulcerative colitis
10.12092/j.issn.1009-2501.2024.03.001
- Author:
Xin SU
1
;
Lin LUO
1
;
Xin SU
2
Author Information
1. School of Pharmacy, Nantong University
2. Tongling Maternal and Child Health Care Hospital
- Publication Type:Journal Article
- Keywords:
Buzhongyiqi pills;
KEGG;
network pharmacology;
ulcerative colitis;
UPLC-QE-MS
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(3):241-251
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To explore the anti-ulcerative colitis mechanism of Buzhongyiqi pills based on the network pharmacology and experimental verification. METHODS: UPLC-QE-MS was used for qualitative analysis of Buzhongyiqi pills. Targets of the chemistry constituents and the disease were retrieved from GeneCards. Then the protein-protein interaction (PPI) network was constructed and core targets were screened for GO term enrichment and KEGG pathway enrichment. Ulcerative colitis mouse model was established to verify the key targets. RESULTS: A total of 41 constituents migrating of Buzhongyiqi pills were identified. A total of 123 common targets of the constituents and the disease and 24 core targets were screened out.KEGG enrichment and PPI network analysis showed that Buzhongyiqi pills may play a role in the treatment of ulcerative colitis through Akt, PI3K and other pathways. Furthermore, the results of animal experiments showed that Buzhongyiqi pills could significantly improve the depression behaviors of ulcerative colitis, reduce the levels of IL-6 and TNF-α in serum, inhibition Akt/PI3K signaling, and reduce the protein expression of PI3K. CONCLUSION: Buzhongyiqi pills may play a role in the treatment of ulcerative colitis by inhibition Akt / PI3K signaling pathway, and inhibiting PI3K and reduce the levels of IL-6 and TNF-α in the mice.
